Geoffrey R. Weiss - Concepedia

Author

Geoffrey R. Weiss

The University of Texas Health Science Center at San Antonio ORCID

Also Known As

C Britten, G R Weiss, G WEISS, G Weiss, G. R. Weiss, G. Weiss, G.R. WEISS, G.R. Weiss, GEOFFREY R. WEISS, GEOFFREY WEISS

245

Publications

17.1K

Citations

H-Index

128

Concepts

All Affiliations

The University of Texas Health Science Center at San Antonio City Of Hope National Medical Center SWOG Cancer Research Network Cancer Research And Biostatistics Brooke Army Medical Center

About

Geoffrey R. Weiss is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	74	5.9K
2	Health Sciences	12	15	1.8K
3	Education	1	1	14
4	Management	1	1	23
5	Nursing	1	1	14

Geoffrey R. Weiss

142

Publications

14.6K

Citations

H-Index

Page 1

	Year	Citations
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial Karen Kelly, John Crowley, Paul A. Bunn, Journal of Clinical Oncology	2001	1.1K
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma David F. McDermott, Meredith M. Regan, Joseph I. Clark, Journal of Clinical Oncology	2004	814
A Southwest Oncology Group study Terry R. Jenkins, Catherine M. Tangen, John S. Macdonald, Surgical OncologyGastrointestinal PharmacologyAdvanced Gastric CancerSouthwest Oncology GroupCancer Management	1993	775
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria Stephanie Green, Geoffrey R. Weiss Investigational New Drugs OncologyToxicity CriteriaCancer ManagementSouthwest Oncology GroupClinical Endpoint	1992	613
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. Agnieszka Woźniak, John J. Crowley, S P Balcerzak, Journal of Clinical Oncology	1998	566
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. Karen H. Antman, John Crowley, S P Balcerzak, Journal of Clinical Oncology	1993	477
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. Cynthia G. Leichman, Thomas R. Fleming, Franco M. Muggia, Journal of Clinical Oncology	1995	360
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. Mace L. Rothenberg, John R. Eckardt, John G. Kuhn, Journal of Clinical Oncology	1996	351
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. Kim Margolin, Anthony A. Rayner, Michael Hawkins, Journal of Clinical Oncology Management GuidelinesSolid TumorsImmunologyImmunoeditingMetronomic Chemotherapy	1989	347
Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial Joseph I. Clark, Michael B. Atkins, Walter J. Urba, Journal of Clinical Oncology	2003	311

Page 1